These findings reveal a potential additive effect of copper depletion and BRAF inhibition, thus suggesting that copper chelation therapy combined with pharmacological treatment with PLX4720 would provide a better therapeutic response in BRAFV600E mutant colorectal cancer cells, which were otherwise unresponsive to vemurafenib or its analogue compounds treatments. The gene discussed is BRAF; the disease is colorectal cancer.